BCMAxCD3 and Anti-CD38 Antibodies for T Cell Exhaustion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tumors evade immune recognition by creating an immunosuppressive tumor microenvironment, leading to T cell exhaustion and impaired functionality, which impairs the efficacy of T cell redirecting therapeutics in treating cancers.
Innovation Solution
The use of a BCMAxCD3 bispecific antibody and an anti-CD38 antibody, comprising specific amino acid sequences, to enhance T cell functionality and improve the efficacy of T cell redirecting therapeutics in treating multiple myeloma, including administering these antibodies separately or in combination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If T cell redirecting therapeutics are used to target solid tumors, then tumor cell recognition is improved, but T cell activation and proliferation are inhibited due to hypoxic conditions
Solution Approach 1:
The patent introduces oxygen-carrying particles (hyperoxic particles) as intermediaries to transport oxygen from the bloodstream to hypoxic tumor regions. These particles act as a mediator between the oxygen-rich blood supply and the oxygen-deprived tumor microenvironment, enabling T cells to function properly without directly exposing them to high oxygen concentrations systemically.
Solution Approach 2:
The tumor microenvironment itself is utilized to release oxygen from the particles through the hypoxic conditions, which naturally trigger oxygen release. The hypoxic tumor region serves its own function of activating the oxygen-carrying particles to deliver oxygen precisely where needed, without requiring external activation mechanisms.
2Productivity
If conventional chemotherapy or radiation is used, then tumor growth is slowed, but T cell function is suppressed and normal tissue damage occurs
Solution Approach 1:
The patent extracts and isolates the oxygen delivery function from conventional chemotherapy and radiation approaches. By using oxygen-carrying particles to specifically deliver oxygen to tumor regions, the treatment separates the beneficial anti-tumor effects from the harmful immunosuppressive effects of conventional therapies.
Solution Approach 2:
The patent changes the oxygen concentration parameter specifically in the tumor microenvironment by introducing hyperoxic particles. This localized parameter change activates T cells and enhances anti-tumor immunity without systemically altering oxygen levels that would affect normal tissues and immune function.
3Reliability
If T cells are activated systemically, then anti-tumor immunity is enhanced, but off-target effects and autoimmune reactions increase
Solution Approach 1:
The patent applies local quality by creating a hyperoxic microenvironment specifically at the tumor site through oxygen-carrying particles. This localized oxygen enrichment activates T cells only in the tumor region, maintaining high anti-tumor immunity while avoiding systemic activation that would cause off-target effects and autoimmune reactions.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.